CLOs on the Move

Abengoa Bioenergy Corporation

www.abengoabioenergy.com

 
Abengoa Bioenergy Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Slingshot Biosciences

Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.

The Canadian Cancer Research Group

The Canadian Cancer Research Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Mid Atlantic Technology and Enviromental Research In

Mid Atlantic Technology & Enviromental Research In is a Castle Hayne, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sesen Bio

We are passionate in our commitment to improving and renewing people`s lives. Sesen Bio is a late-stage company devWe are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company`s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.eloping fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body`s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium`s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors.

Medical Business Resources

Medical Business Resources, Inc., established in 1994 as a medical billing service, offers a cost effective solution to the complexities of medical practice administration. Our services allow providers to focus upon delivering health care with the confidence that administrative support services are in place.